Brokerages expect Mylan (NASDAQ:MYL) to report earnings of $1.41 per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Mylan’s earnings, with the lowest EPS estimate coming in at $1.33 and the highest estimate coming in at $1.50. Mylan reported earnings per share of $1.57 during the same quarter last year, which indicates a negative year-over-year growth rate of 10.2%. The company is scheduled to announce its next earnings report after the market closes on Wednesday, February 28th.
On average, analysts expect that Mylan will report full year earnings of $4.54 per share for the current year, with EPS estimates ranging from $4.45 to $4.65. For the next fiscal year, analysts anticipate that the firm will post earnings of $5.34 per share, with EPS estimates ranging from $5.12 to $5.52. Zacks’ EPS averages are an average based on a survey of analysts that cover Mylan.
A number of equities analysts have recently commented on MYL shares. Zacks Investment Research cut shares of Mylan from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the company a “hold” rating in a report on Tuesday, October 31st. Guggenheim started coverage on shares of Mylan in a report on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price on the stock. Citigroup reaffirmed a “buy” rating and issued a $58.00 target price (up from $48.00) on shares of Mylan in a report on Thursday, January 4th. Finally, Wells Fargo & Co set a $43.00 target price on shares of Mylan and gave the company a “hold” rating in a report on Thursday, January 18th. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $44.89.
Mylan (NASDAQ:MYL) traded up $0.17 during mid-day trading on Wednesday, reaching $41.45. 2,797,958 shares of the company’s stock were exchanged, compared to its average volume of 5,650,000. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82. The firm has a market capitalization of $22,140.00, a PE ratio of 24.97, a P/E/G ratio of 1.12 and a beta of 1.35.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.69% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Rehmann Capital Advisory Group purchased a new stake in shares of Mylan during the 4th quarter worth $236,000. Xact Kapitalforvaltning AB boosted its position in shares of Mylan by 11.5% during the 4th quarter. Xact Kapitalforvaltning AB now owns 80,209 shares of the company’s stock worth $3,394,000 after purchasing an additional 8,249 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Mylan by 23.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 8,283 shares of the company’s stock worth $349,000 after purchasing an additional 1,596 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of Mylan by 9.9% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 180,616 shares of the company’s stock worth $7,642,000 after purchasing an additional 16,260 shares in the last quarter. Finally, Paragon Capital Management LLC purchased a new stake in shares of Mylan during the 4th quarter worth $260,000. Institutional investors own 76.86% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “$1.41 Earnings Per Share Expected for Mylan (MYL) This Quarter” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/24/1-41-earnings-per-share-expected-for-mylan-myl-this-quarter.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Get a free copy of the Zacks research report on Mylan (MYL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.